KliniKomputer

Health is a precious treasure for us. Imagine if we are sick, how much revenue will be wasted, and how much money we spend on medication. The most important factor that we are healthy immune against all kinds of viruses, free radicals, and other diseases.

Oxis is developing and plans to sell products and nutraceutical Cosmecuetical with natural ingredients, believed to have beneficial effects on human health. Oxis first products will include the L-ERGOTHIONEINE (ergo) as a key component. Ergo is a powerful antioxidant, multi-faceted nature of the ergo exceptional described in detail in the section of this site ERGOTHIONEINE. Oxis patented the synthesis of L-and ERGOTHIONEINE outsourcing the manufacture of products for a company that can provide ergo GMP production in commercial quantities and to meet the needs of our products.
OXIS’ consumer products strategy addresses very important health concerns including aging and age-related disorders that are increasing with trends in US demographics.  These concerns include:

• Brain health
• Immunity against diseases
• Anti-aging/skin health
• Inflammation
• Detoxification
• Blood sugar regulation

The lead compound is BXT-51072, that is a low molecular weight, orally active, organoselenium catalytic mimic of one of the major cellular protective antioxidant enzyme, glutathione peroxidase (GPx) which uses glutathione as substrate.  BXT-51072 can be taken orally or administered intravenously. In addition to its direct hydrogen peroxide (a central reactive oxygen species) neutralizing capabilities, BXT-51072 regulates secondary inflammatory processes by preventing the activation and release of inflammatory mediators such as cytokines, adhesion molecules and inflammatory enzymes. The exact mechanism is unclear but there is evidence that BXT-51072 may function by inhibiting fundamental nuclear transcription mechanisms that govern and regulate inflammation and other significant processes.   BXT-51072 was initially developed for use in the treatment of inflammatory bowel diseases, and has demonstrated efficacy and safety in a preliminary Phase 2 study for ulcerative colitis.